These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919 [TBL] [Abstract][Full Text] [Related]
27. Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients. Wang B; Yu X; Xu S; Xu M Medicine (Baltimore); 2016 Jan; 95(4):e2611. PubMed ID: 26825914 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704 [TBL] [Abstract][Full Text] [Related]
29. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662 [TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience. Schmitt T; Kosely F; Wuchter P; Schmier JW; Ho AD; Egerer G Onkologie; 2013; 36(7-8):415-20. PubMed ID: 23921760 [TBL] [Abstract][Full Text] [Related]
32. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS Oncology; 2019; 96(2):59-69. PubMed ID: 30336470 [TBL] [Abstract][Full Text] [Related]
33. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471 [TBL] [Abstract][Full Text] [Related]
34. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A; Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293 [TBL] [Abstract][Full Text] [Related]
35. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382 [TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. Choi Y; Yun MS; Lim SH; Lee J; Ahn JH; Kim YJ; Park KH; Park YS; Lim HY; An H; Suh DC; Kim YH Cancer Res Treat; 2018 Jan; 50(1):175-182. PubMed ID: 28361521 [TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358 [TBL] [Abstract][Full Text] [Related]
39. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. He A; Qi W; Huang Y; Sun Y; Shen Z; Zhao H; Yang Y; Yao Y Int J Clin Oncol; 2013 Jun; 18(3):498-505. PubMed ID: 22534798 [TBL] [Abstract][Full Text] [Related]
40. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]